Searchable abstracts of presentations at key conferences in endocrinology

ea0012p90 | Pituitary | SFE2006

Cabergoline is an effective and well tolerated primary and adjunctive treatment for acromegaly

Moyes VJ , Metcalfe KA , Drake WM

Cabergoline is a dopamine agonist that may be used as primary or adjunctive therapy for acromegaly. Although one study suggested biochemical control may be achieved in a substantial proportion of patients (Abs et al, JCEM 1998), it is still commonly perceived to be a relatively ineffective treatment, possibly on account of inadequate dosing.We performed a retrospective case notes review of 9 consecutive acromegalic patients to determine the effectiveness...

ea0019p227 | Pituitary | SFEBES2009

Effect of the d3 growth hormone receptor genotype on GH responsiveness in adult hypopituitary patients

Moyes VJ , Walker D , Owusu-Antwi S , Maher KT , Metherell L , Akker SA , Monson JP , Clark AJ , Drake WM

Objective: Variability in growth hormone (GH) responsiveness is evident in adult hypopituitary patients receiving recombinant GH (rhGH). Doses vary up to 4-fold for unexplained reasons. Deletion of exon 3 in the GH receptor (d3-GHR) has been linked to an increased response to GH treatment in children, although data are conflicting. We investigated the role of the d3-GHR polymorphism in determining GH responsiveness in adult GH deficient patients.Methods:...